# Carver Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/carver-biosciences

- Industry: Healthcare
- Headquarters: Boston, US
- Website: www.carver.bio
- Total disclosed funding: $3M
- Latest round: Seed (Sep 15, 2021)
- Investors on record: 1

## About

Based in Massachusetts, US, and founded in 2021 by Walter R. Strapps (CEO), and Cameron Myhrvold (Assistant Professor), Carver Biosciences operates as a healthcare company that offers solutions for treating different viruses that affect humans. In September 2022, Carver Biosciences raised a seed round led by Khosla Ventures. 

Carver Biosciences created Cas13-based technology to treat patients infected with respiratory viruses. This technology provides a programmable platform for treating various existing viruses as well as quickly responding to new viruses as they emerge.

The company plans to use September 2022 funding to conduct initial proof of concept Cas13 experiments in cells and in models of disease at their laboratories in Boston and with CRO partners.

## Funding rounds

- Seed, Sep 15, 2021, $3M — Khosla Ventures

## Investors

- Khosla Ventures (https://capitalatlas.ai/funds/khosla-ventures) — Seed